Literature DB >> 7367824

Functioning liver mass in uncomplicated and fulminant acute hepatitis.

K Ramsøe, P B Andreasen, L Ranek.   

Abstract

The galactose elimination capacity and the plasma clearance of phenazone were investigated in 24 patients with uncomplicated acute hepatitis and in 8 patients who survived and in 26 who died of fulminant hepatitis. The galactose elimination capacity was 52% of the normal mean value on admission to the hospital in uncomplicated hepatitis, 47% in patients who survived fulminant hepatitis, and 22% in the fatal cases, while the plasma clearance of phenazone was 43%, 22%, and 10%, respectively. Both quantitative liver function tests showed rapid improvement in most cases of uncomplicated acute hepatitis and in the patients who survived fulminant hepatitis. They did not improve in the fatal cases of fulminant hepatitis, among whom the patients with the lowest initial values died first. Both the galactose elimination capacity and the plasma clearance of phenazone were significantly higher in survivors than in non-survivors of fulminant hepatitis. The results indicate that the loss of functioning liver cell mass is about 60-70% in the acute stage of uncomplicated hepatitis and 80-85% in patients who survive fulminant hepatitis, whereas patients who die of fulminant hepatitis have nearly total loss of functioning liver cell mass.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7367824     DOI: 10.3109/00365528009181434

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices.

Authors:  T Kano; T Kojima; T Takahashi; Y Muto
Journal:  Gastroenterol Jpn       Date:  1987-06

2.  Diagnosis of acute drug-induced liver injury. Usefulness of clinicopathological patterns and biochemical indices.

Authors:  M Døssing; P B Andreason
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 3.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

4.  Rapid inhibition of DNA synthesis in hepatocytes from regenerating rat liver by serum from patients with fulminant hepatic failure.

Authors:  C D Gove; R D Hughes; R Williams
Journal:  Br J Exp Pathol       Date:  1982-10

5.  Reticuloendothelial system and hepatocytic function in fulminant hepatic failure.

Authors:  J Canalese; C D Gove; A E Gimson; S P Wilkinson; E N Wardle; R Williams
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

6.  Human hepatocyte growth factor in blood of patients with fulminant hepatic failure. I. Clinical aspects.

Authors:  H Tsubouchi; S Hirono; E Gohda; H Nakayama; K Takahashi; O Sakiyama; M Kimoto; S Kawakami; H Miyoshi; O Kubozono
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.